Plain-English translation of NCT06242470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing MGC026, a new type of cancer medication that combines a cancer-fighting drug with a protein that helps target tumor cells. Researchers want to find the right dose, understand how safe it is, and see if it can help slow or shrink advanced cancers that have spread or cannot be removed by surgery. You would receive the medication through an IV infusion every three weeks.
Many people with advanced cancers do not respond well to existing treatments. This medication is designed to work differently by attaching a cancer-fighting agent directly to a protein found on cancer cells, potentially offering a new option for patients with cancers that have become resistant to standard therapies.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the medication through an IV every three weeks, with the possibility of receiving up to 35 treatments if you tolerate it well and your cancer does not worsen. Throughout the study, you would have regular visits for blood tests, imaging scans to track your tumor, and medical exams to monitor for side effects. The study involves both a dose-escalation phase (where researchers find the safest dose) and an expansion phase (where they test that dose in more patients with specific cancer types).
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States